Tretten (Coagulation factor XIII A-subunit [recombinant]) for Hemophilia

Overview Tretten is approved by the Food and Drug Administration (FDA) for routine prophylaxis in children and adults with congenital factor XIII A-subunit deficiency. The technical name of Tretten is Coagulation factor XIII A-subunit (recombinant). Tretten is a clotting factor. Clotting factors work by supplying proteins missing in people with certain bleeding disorders. How do I take it? Prescribing information states that Tretten is given as an intravenous injection. Tretten comes as a powder that must be reconstituted before injection. Side effects The FDA-approved label for Tretten lists common side effects including headache, pain in the extremities, injection site reactions, and changes in blood test results. Rare but serious side effects listed for Tretten include hypersensitivity reactions, thrombosis (dangerous blood clots forming in blood vessels), and the development of inhibitors. For more details about this treatment, visit: Tretten - Novo Nordisk http://www.tretten.com/ Treatment of Hemophilia - Hemophilia Federation of America http://www.hemophiliafed.org/bleeding-disorders/hemophilia/treatment/